Activation of Wnt signalling reduces the population of cancer stem cells in ameloblastoma

The treatment of ameloblastoma, an odontogenic epithelial tumour destroying jawbone, mainly depends on radical destructive resections. Other therapeutic options are limited by the characteristics of ameloblastoma, such as high recurrence rates and resistance to radiation and chemotherapy, which implies possible existence of cancer stem cells (CSCs) in ameloblastoma. Here, we identified a putative CSC population in immortalized and primary human ameloblastoma cells and examined possible therapeutic reagents to reduce the CSC population.

[1]  Asher Mullard,et al.  Smallest biopharma firms are pushing more of the pipeline , 2019, Nature Reviews Drug Discovery.

[2]  L. Suva,et al.  Treatment with anti‐Sclerostin antibody to stimulate mandibular bone formation , 2018, Head & neck.

[3]  M. McClung.  Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential , 2017, Therapeutic advances in musculoskeletal disease.

[4]  J. Grandis,et al.  The fourth edition of the head and neck World Health Organization blue book: editors' perspectives. , 2017, Human pathology.

[5]  A. Engelbrecht,et al.  Cancer stem cells: A product of clonal evolution? , 2017, International journal of cancer.

[6]  K. Nakano,et al.  Parenchyma–stromal interactions induce fibrosis by secreting CCN2 and promote osteoclastogenesis by stimulating RANKL and CD68 through activated TGF‐&bgr;/BMP4 in ameloblastoma , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[7]  A. Carnero,et al.  The cancer stem-cell signaling network and resistance to therapy. , 2016, Cancer treatment reviews.

[8]  G. Devi,et al.  Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. , 2016, Pharmacology & therapeutics.

[9]  D. Hampson,et al.  The Calcium-Sensing Receptor and Integrins in Cellular Differentiation and Migration , 2016, Front. Physiol..

[10]  S. Millar,et al.  Beta-catenin is essential for ameloblast movement during enamel development. , 2016, European journal of oral sciences.

[11]  M. Hirata,et al.  Surface vacuolar ATPase in ameloblastoma contributes to tumor invasion of the jaw bone. , 2016, International journal of oncology.

[12]  Han-Sung Jung,et al.  Sox2 contributes to tooth development via Wnt signaling , 2016, Cell and Tissue Research.

[13]  R. West,et al.  Ameloblastoma: a clinical review and trends in management , 2016, European Archives of Oto-Rhino-Laryngology.

[14]  H. Kleinman,et al.  Matrigel: from discovery and ECM mimicry to assays and models for cancer research. , 2014, Advanced drug delivery reviews.

[15]  R. West,et al.  Identification of recurrent SMO and BRAF mutations in ameloblastomas , 2014, Nature Genetics.

[16]  S. Chiou,et al.  Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression. , 2014, Stem cell research.

[17]  Yanqing Huang,et al.  Self-renewal and multilineage differentiation of mouse dental epithelial stem cells. , 2013, Stem cell research.

[18]  Seiji Nakamura,et al.  Anti-apoptotic role of the sonic hedgehog signaling pathway in the proliferation of ameloblastoma , 2013, International journal of oncology.

[19]  K. Hochedlinger,et al.  Sox2 marks epithelial competence to generate teeth in mammals and reptiles , 2013, Development.

[20]  H. Nagatsuka,et al.  Osteogenic genes related to the canonic WNT pathway are down-regulated in ameloblastoma. , 2012, Oral surgery, oral medicine, oral pathology and oral radiology.

[21]  K. Hochedlinger,et al.  Sox2+ stem cells contribute to all epithelial lineages of the tooth via Sfrp5+ progenitors. , 2012, Developmental cell.

[22]  Jennifer J Westendorf,et al.  Update on Wnt signaling in bone cell biology and bone disease. , 2012, Gene.

[23]  H. Kumamoto,et al.  Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[24]  H. Nagatsuka,et al.  Secreted frizzled related protein (sFRP)-2 inhibits bone formation and promotes cell proliferation in ameloblastoma. , 2009, Oral oncology.

[25]  James C. Leong,et al.  Mandibular ameloblastoma: clinical experience and literature review , 2009, ANZ journal of surgery.

[26]  Seiji Nakamura,et al.  Inhibition of Akt and MAPK pathways elevated potential of TNFalpha in inducing apoptosis in ameloblastoma. , 2006, Oral oncology.

[27]  T. Kukita,et al.  Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. , 2005, Oral oncology.

[28]  L. Hendarmin,et al.  TNFalpha played a role in induction of Akt and MAPK signals in ameloblastoma. , 2005, Oral oncology.

[29]  N. Nakamura,et al.  Midkine induced growth of ameloblastoma through MAPK and Akt pathways. , 2004, Oral oncology.

[30]  A. Taniguchi,et al.  Establishment of ameloblastoma cell line, AM-1. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.